What is the global market size of Neuroendocrine Tumors Treatment Market?

Neuroendocrine Tumors Treatment Market size was valued at USD 1.57 billion in 2021 and is poised to grow from USD 1.7 billion in 2022 to USD 3.29 billion by 2030, growing at a CAGR of 8% in the forecast period (2023-2030).

Global Neuroendocrine Tumors Treatment Market Size, Share, Growth Analysis, By Treatment Type(Somatostatin Analogy, Targeted Therapy), By End user(Hospitals, Clinics), By Indication(Gastric Neuroendocrine Tumors, Lung Neuroendocrine Tumors) - Industry Forecast 2024-2031

Report ID: SQSG35I2023 | Region: Global | Published Date: April, 2024
Pages: 165 | Tables: 90 | Figures: 76

Global Neuroendocrine Tumors Treatment Market Insights

Neuroendocrine Tumors Treatment Market size was valued at USD 1.57 billion in 2019 and is poised to grow from USD 1.7 billion in 2023 to USD 3.29 billion by 2031, growing at a CAGR of 8% in the forecast period (2024-2031).

The prevalence of cancers is rising significantly on a global scale. Rare tumors called neuroendocrine tumors (NET) develop from the cells of the neurological system and endocrine/hormonal system. Known as carcinoid tumors, neuroendocrine tumors typically develop in the gastrointestinal tract but can also develop in the appendix, rectum, pancreas, and lungs. Neuroendocrine tumors can either have a benign or cancerous nature.

Constipation, diarrhea, stomachaches, chronic coughing, low blood sugar, changes in blood pressure, heart problems, and other symptoms are all signs of neuroendocrine tumors. Rising neuroendocrine tumor prevalence, increased R&D spending, new product introductions, and early detection thanks to improved diagnostic methods are expected to accelerate the market for treatments for neuroendocrine tumors worldwide over the forecast period.

US Neuroendocrine Tumors Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.

Global Neuroendocrine Tumors Treatment Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Due to the presence of a sizable number of participants, the market is quite competitive. To increase their consumer base, the majority of businesses are engaging in strategic alliances like mergers and acquisitions. To draw in more customers, players are diversifying their product offerings. 'Novartis International AG', 'Pfizer Inc.', 'Ipsen Biopharmaceuticals, Inc.', 'Advanced Accelerator Applications (AAA)', 'F. Hoffmann-La Roche Ltd.', 'Teva Pharmaceutical Industries Ltd.', 'Exelixis, Inc.', 'Celgene Corporation', 'Amgen, Inc.', 'Merck & Co., Inc.', 'Mylan N.V.', 'Progenics Pharmaceuticals, Inc.', 'AbbVie, Inc.', 'Eisai Co., Ltd.', 'Ipsen Group', 'Curium Pharma', 'Ipsen S.A.', 'Endo Pharmaceuticals, Inc.', 'Spectrum Pharmaceuticals, Inc.', 'Bayer AG'

A rise in the incidence of neuroendocrine tumors is expected to drive the market: The incidence and prevalence of neuroendocrine tumors (NET) are steadily rising worldwide, according to the data from the American Society of Clinical Oncology (ASCO). Because of this, the adoption rate of the medications for the treatment of this rare condition is aided by the rising prevalence of neuroendocrine tumors.

The neuroendocrine tumor treatment market is anticipated to be dominated by somatostatin analogs: As they limit tumor growth, symptoms, and biomarkers, somatostatin analogs (SSAs) are discovered to be the medications most frequently utilized to treat the neuroendocrine tumor. Due to the safe treatment methods provided by SSAs, they account for the greatest revenue share. Patients who are sensitive to radiotherapy and surgery are found to typically be treated with SSAs. Since many SSAs are presently in the clinical trial stage and awaiting approval, the market is anticipated to have rapid growth throughout the forecast period.

Based on region, North America is predicted to experience considerable growth in the neuroendocrine tumor treatment market, due to the increasing acceptance of novel neuroendocrine tumor treatments in the region. For instance, Ipsen's Somatuline Depot (lanreotide) Injection 120 mg was approved by the U.S. Food and Drug Administration (FDA) and it is intended for the treatment of adults with advanced or metastatic, moderately-differentiated, locally advanced, or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Global Neuroendocrine Tumors Treatment Market Size, Share, Growth Analysis, By Treatment Type(Somatostatin Analogy, Targeted Therapy), By End user(Hospitals, Clinics), By Indication(Gastric Neuroendocrine Tumors, Lung Neuroendocrine Tumors) - Industry Forecast 2024-2031

Global Neuroendocrine Tumors Treatment Market Insights

Global Neuroendocrine Tumors Treatment Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Neuroendocrine Tumors Treatment Market?

Who are the key vendors in the Global Neuroendocrine Tumors Treatment Market?

What is the key driver of Global Neuroendocrine Tumors Treatment Market?

What is the key market trend for Global Neuroendocrine Tumors Treatment Market?

Which region accounted for the largest share in Global Neuroendocrine Tumors Treatment Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300